MetLife, Inc.

▲ Bull Case

• ◆GAAP/Adj. EPS confusion creates a systematic mispricing: GAAP P/E ~14x appears fair and investors pass, but Adj. P/E is ~7.5x on a 16% ROE business — deep value. The ~$4.18/share AOCI gap is 100% non-cash and reverses mechanically as bonds mature to par, requiring no speculative assumptions.
• ◆9.6% total annual shareholder yield ($3.1B buybacks + $1.3B dividends at $67/share) on a capital-generating machine: buybacks retire ~4-5% of float annually, producing ~25% EPS accretion over 5 years from share count reduction alone, independent of earnings growth or multiple expansion.
• ◆Three concurrent growth drivers compound simultaneously: NII expansion ($50-100M/yr mechanically as the $400-500B portfolio rolls to higher yields), Group Benefits repricing (3/3 prior cycles fully normalized in 18-30 months; Q4 2025 showed +12% QoQ recovery), and record PRT supercycle ($14.2B single quarter in Q4 2025 driven by US pension funded status at 103%, a 20-year high).

▼ Bear Case

• ◆Group Benefits softness is structural, not cyclical: post-COVID behavioral shifts have permanently elevated mental health and long-term disability claims; employers resist large premium increases; loss ratio stays elevated above 88-90%, invalidating the repricing thesis and compressing segment earnings durably.
• ◆Fed cuts 200bps+ reverses the NII expansion tailwind: if rates fall sharply, new money yields drop toward the portfolio average, the mechanical roll benefit stalls or reverses, and the primary earnings growth engine disappears — forcing earnings estimates down and compressing the justified multiple.
• ◆MetLife Holdings adverse reserve development: a reserve charge exceeding $1.5B on legacy variable annuities or long-term care would force capital redeployment away from buybacks, shrink the capital return program, and signal that the closed-block runoff is more dangerous than modeled — the single largest tail risk to the thesis.

“The central debate is GAAP vs. Adjusted EPS. Bears argue GAAP EPS is the only audited number and 14x GAAP P/E is fair value; if MetLife cannot report clean earnings, the complexity itself is a discount factor. Bulls counter that the AOCI is 100% non-cash, results entirely from the 2022 rate spike on AFS bonds, and reverses mechanically as bonds mature to par — analysts using GAAP EPS for insurers with large AFS portfolios are making a fundamental accounting error, and 7.5x adj. EPS on 16% adj. ROE is deep value. The secondary debate is whether Group Benefits repricing is real (bulls: 3/3 prior cycles normalized in 18-30 months; Q4 2025 +12% QoQ recovery is the signal) or whether behavioral shifts post-COVID have permanently impaired the segment (bears). Resolution on both fronts is observable quarterly: track GAAP EPS improvement as AOCI reverses, and track Group Benefits loss ratio convergence toward 86-88%.”

• ◆Q2 2026 Group Benefits loss ratio improving QoQ — confirms repricing cycle on track and reduces bear scenario probability
• ◆FY2026 adj. EPS ≥$9.91 (consensus) — removes execution risk and begins multiple re-rating from 7.5x
• ◆FY2026 PRT volume $35B+ — confirms structural supercycle driven by 103% pension funded status, not one-time quarter
• ◆Q4 2026/Q1 2027 AOCI reversal becomes visible in quarterly GAAP reports — generalist investors rediscover MET and the GAAP/Adj. gap narrows
• ◆MIM external AUM crosses $100B — triggers capital-light earnings re-rating and diversifies the earnings stream

• ◆Group Benefits loss ratio >90% for 3+ consecutive quarters — signals structural impairment; repricing thesis fails; bear case becomes base case (15% probability, HIGH severity)
• ◆Fed cuts 200bps+ causing NII guidance cut below $22.5B — reverses the primary earnings growth engine (15-20% probability, HIGH severity)
• ◆MetLife Holdings reserve charge >$1.5B — adverse development beyond actuarial review threshold; forces capital redeployment away from buybacks; severe scenario probability spikes (5% probability, HIGH severity)
• ◆Buybacks suspended for >2 consecutive quarters — signals impaired capital generation; entire mechanical EPS accretion story depends on ~$3B/yr continuous repurchase
• ◆Sustained JPY weakness (>160/USD) — meaningful drag on Asia segment (~20% of earnings) though not alone thesis-breaking (20% probability, MODERATE severity)